American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.

Idrugs Pub Date : 2010-09-01
Gary Croasdell
{"title":"American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.","authors":"Gary Croasdell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"598-600"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国糖尿病协会-第70届科学会议-新疗法的研究:第2部分。
美国糖尿病协会第70届科学会议在美国佛罗里达州奥兰多举行,主题包括糖尿病研究领域的新治疗发展。本会议报告重点介绍了使用新型药物进行的新研究。讨论的研究药物包括葡萄糖激酶激活剂SKL-19014 (Sanwa Kagaku Kenkyusho Co . Ltd .), GPR119激动剂AS-1535907 (Astellas Pharma Inc .),顶钠依赖性胆转运蛋白(ASBT)抑制剂SC-435 (Satiogen Pharmaceuticals Inc .), VEGF-A激活剂SB-509 (Sangamo BioSciences Inc .)和蛋白酪氨酸磷酸酶1b (PTP-1b)反义抑制剂ISIS-113715 (ISIS Pharmaceuticals Inc .)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Idrugs
Idrugs 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Neurodegenerative diseases. Edotecarin. Tesaglitazar. Anti-inflammatory drugs Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1